Breakthrough lung cancer drug gets MHRA green light

Latest

Breakthrough lung cancer drug gets MHRA green light

In Latest

A cutting-edge treatment for lung cancer patients has provisionally been given the green light in the UK, meaning NHS patients will be the first in Europe to be offered it.

Sotorasib, which is taken as a tablet and is marketed as Lumykras, was granted a conditional marketing authorisation by the MHRA on Friday. It targets KRAS G12C, a mutation found in a quarter of all tumours, and has been shown to permanently lock it in an inactive state and prevent cell growth, says manufacturer Amgen UK.  

The NHS will begin offering the drug to eligible lung cancer patients within weeks through an early access agreement with Amgen, while NICE completes its appraisal process.

The announcement follows a 40-year search for a treatment for KRAS G12C. It has been approved as part of Project Orbis, an international programme between the US FDA and other regulatory agencies aimed at speeding up the review of new oncology medicines.

Described as the first drugof its kind, it is hoped that sotorasib could offer a breakthrough in the treatment of other deadly cancers including pancreatic and colorectal cancers.

Dr. Tony Patrikios, executive medical director at Amgen UK and Ireland, said: “Today’s conditional marketing authorisation by the MHRA marks an important moment in treating lung cancer patients, with a new targeted therapy, who have failed first-line treatment and face extremely poor outcomes with limited further treatment options.

“This reflects the clinical investigation programme, demonstrating the use of sotorasib in adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.”

“Sotorasib is the first targeted KRAS G12C inhibitor to be authorised for use in Great Britain. Targeting KRAS has been a 40-year quest by scientists and researchers around the World. Approximately 13 per cent of patients with NSCLC harbour the KRAS G12C mutation and whilst approximately 48,000 people are diagnosed with lung cancer every year in the UK  it is estimated that 5,000 of these people will have KRAS G12C-mutated NSCLC.”

Professor Charles Swanton, Cancer Research UK’s chief clinician, said: “Sotorasib is one of the most exciting breakthroughs in lung cancer treatment in 20 years, targeting a cancer gene that was previously untargetable and built on decades of laboratory research that’s unravelled cancer’s inner workings.

“This medicine expands our list of effective precision therapies in lung cancer that are helping to improve survival for patients with limited options. It’s great news that patients in England will now benefit from this novel treatment.”

Record my learning outcomes

Latest

Inspiring stories related to health, fitness and the pursuit of wellbeing

Share:

More like this

bookmark_icon_off
Latest

Flu jabs can now be given 'anywhere in the pharmacy'

Community pharmacists will be able to provide flu vaccinations “in any appropriate space within the pharmacy” this flu season, says NHS England. 

1 Min Article

bookmark_icon_off
Latest

People from deprived areas visit A&E in larger numbers

Nearly twice as many people who went to A&E came from the 10 per cent of the population living in the most deprived areas

1 Min Article

bookmark_icon_off
Latest

Phoenix: Budget 'a slap in the face' to pharmacies

Anderson warned that 30 to 50 per cent of pharmacies “could close in the next few years".

1 Min Article

bookmark_icon_off
Latest

New pharmacy quality scheme starts on September 1

The 2021-22 scheme will again contain seventy-five million pounds in funding.

1 Min Article

bookmark_icon_off
Latest

People in contact with secondary mental health on rise

Over 2.8 million people were recorded as being “in contact” with secondary mental health services in 2019-20.

1 Min Article

bookmark_icon_off
Latest

PHE launches cervical screening campaign

PHE has launched a campaign – Cervical Screening Saves Lives – to encourage women to accept their cervical screening invitation.

1 Min Article

Recommended Learning

bookmark_icon_off
Videos

Supporting daily digestive health

Learn about the crucial role of gut bacteria and how a healthy microbiome can support daily digestive health

2 Min Module

bookmark_icon_off
Sponsored education

Frontline Tackling Fleas & Ticks

This NPA-accredited module will enable you to have confident conversations with customers, helping them manage fleas and ticks both on their pets and in the home.

10 Min Module

bookmark_icon_off
Bayer Business Programme

Make it Count: Team Member version

Find out new insights into the consumers of today and explore how, by taking a customer-first approach, you can add value and help build a loyal customer base.

15 Min Module

Sponsored education

Supporting women in their contraceptive choices

Upgrade your contraceptive consultations by exploring the interactive pack to learn about a daily oral contraceptive pill

8 Min Module

bookmark_icon_off
Sponsored education

Men's health how-to guide

This video offers advice and inspiration from pharmacist Ade Williams that you can use to improve your men’s health offering

9 Min Module

bookmark_icon_off
Bayer Business Programme

Make it Count: Manager version

This training offers new insights into the customers of today and explores how you and your team can adapt your sales approach to engage with customers in order to grow your business.

15 Min Module